|
Market Closed -
Nasdaq
01:30:00 24/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.5193 USD | -7.84% |
|
+6.37% | -67.13% |
| 12/10 | Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. | CI |
| 09/10 | Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 13Cr | - | - | - | ||
| 6.47TCr | |||||
| 5.48TCr | |||||
| 5.35TCr | |||||
| 4.6TCr | |||||
| 4.29TCr |
Select your edition
All financial news and data tailored to specific country editions
